Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 20:8:765474.
doi: 10.3389/fmed.2021.765474. eCollection 2021.

Treatment of Inflammatory Bowel Disease: A Comprehensive Review

Affiliations
Review

Treatment of Inflammatory Bowel Disease: A Comprehensive Review

Zhaobei Cai et al. Front Med (Lausanne). .

Abstract

Inflammatory bowel disease (IBD), as a global disease, has attracted much research interest. Constant research has led to a better understanding of the disease condition and further promoted its management. We here reviewed the conventional and the novel drugs and therapies, as well as the potential ones, which have shown promise in preclinical studies and are likely to be effective future therapies. The conventional treatments aim at controlling symptoms through pharmacotherapy, including aminosalicylates, corticosteroids, immunomodulators, and biologics, with other general measures and/or surgical resection if necessary. However, a considerable fraction of patients do not respond to available treatments or lose response, which calls for new therapeutic strategies. Diverse therapeutic options are emerging, involving small molecules, apheresis therapy, improved intestinal microecology, cell therapy, and exosome therapy. In addition, patient education partly upgrades the efficacy of IBD treatment. Recent advances in the management of IBD have led to a paradigm shift in the treatment goals, from targeting symptom-free daily life to shooting for mucosal healing. In this review, the latest progress in IBD treatment is summarized to understand the advantages, pitfalls, and research prospects of different drugs and therapies and to provide a basis for the clinical decision and further research of IBD.

Keywords: Crohn disease; inflammatory bowel disease; recent advance; therapeutics; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. . Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. (2017) 390:2769–78. 10.1016/S0140-6736(17)32448-0 - DOI - PubMed
    1. Pasquali S, Gronchi A. Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. Ther Adv Med Oncol. (2017) 9:415–29. 10.1177/1758834017705588 - DOI - PMC - PubMed
    1. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. (2017) 389:1756–70. 10.1016/S0140-6736(16)32126-2 - DOI - PMC - PubMed
    1. Ocansey DKW, Zhang L, Wang Y, Yan Y, Qian H, Zhang X, et al. . Exosome-mediated effects and applications in inflammatory bowel disease. Biol Rev Camb Philos Soc. (2020) 95:1287–307. 10.1111/brv.12608 - DOI - PMC - PubMed
    1. Nielsen OH, Ainsworth MA. Tumor necrosis factor inhibitors for inflammatory bowel disease. N Engl J Med. (2013) 369:754–62. 10.1056/NEJMct1209614 - DOI - PubMed

LinkOut - more resources